BIOCON LTD. - 532523 - Clarification Of News Item Appearing In Media/Publication
This is with reference to your email dated June 21, 2022, seeking clarification with regards to the media report titled, 'Biocon subsidiary caught offering bribe to waive off trial of new drug'. In this regard, please note that the Company vide its letter dated June 21, 2022, has submitted the Company Statement issued by Biocon Biologics, to the stock exchanges. The aforesaid letter is attached herewith for reference. The Company has always ensured that all material information is disclosed under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). We confirm that there is no unpublished price sensitive information available with the Company and there is no information that is material and not disclosed to the stock exchanges. We are cautious of the regulatory provisions and will be informing the stock exchanges of any such event as per the materiality policy of our company.22-06-2022
